Pivot Park officially welcomed Citryll as the 60th tenant.
“We are very pleased to have Citryll onboard our community, and that they have chosen Pivot Park as the best place to establish their business.” Says Brigitte Drees, CEO of Pivot Park. “Our campus is becoming increasingly interesting because of the ongoing growth in number of companies, people, knowledge and interactions reinforcing each other. We knew the people of Citryll already before and see with them an exciting entrepreneurial spirit that is contagious. A nice contribution to the lively community here at the campus.”
Citryll BV is a private pharmaceutical company that is taking a new approach to treat autoimmune and other human diseases like lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Citryll is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Citryll was founded by ModiQuest B.V., originator of the tACPA patents, Helmuth van Es, CEO Citryll (co-founder of Audion Therapeutics, Galapagos, Antabio and Effecta Pharma), and Renato Chirivi, CSO Citryll and co-inventor of tACPA antibodies. Read more